Supernus Pharmaceuticals Stock Price and Value Analysis

Should you buy Supernus Pharmaceuticals stock? (NasdaqGM:SUPN). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

SUPN Free Cash Flow Trend

Hmm, we can't give any reliable projection for Supernus Pharmaceuticals's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for SUPN
Free Cash Flow trendline for Supernus Pharmaceuticals

Inside the SUPN Numbers

SUPN Price
(Supernus Pharmaceuticals stock price per share)
$46.67
[?] PE Ratio versus Sector 111% higher than other Healthcare stocks
[?] PE Ratio versus Industry 64% lower than other Unknown stocks
[?] Free Cash Flow Jitter 2595%

Is Supernus Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Supernus Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SUPN Stock?

Does Supernus Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.